Clinical trial NCT03809988: PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)
Official title: International,Multicenter,Randomized,Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2nd Line Endocrine Therapy in HR+/HER2- ABC Patients Who Had Clinical Benefit During 1st Line Palbociclib.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Breast Cancer
Advanced Breast Cancer
Hormone Receptor Positive Tumor
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Keywords: HR
breast cancer
ABC
progesterone receptor
HER2
advanced
estrogen receptor
Lead sponsor: MedSIR
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2019-01-18
Enrollment: 198
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized 2:1
Primary purpose: TREATMENT

Brief summary: Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced breast cancer (ABC)

Detailed description: Pre- and post-menopausal women age ≥ 18 years with HR-positive and HER2-negative with ABC that had previously received first-line endocrine therapy in combination with palbociclib and had achieved clinical benefit during palbociclib-based treatment. Patients relapsing on a palbociclib-based regimen in the adjuvant setting are also eligible. Patients are not eligible if they are candidates for a local treatment with a curative intention. Evidence of either measurable and biopsiable metastatic disease (as for Response Evaluation Criteria In Solid Tumors (RECIST v.1.1)) or non-measurable disease with bone lesion is required. Pre-menopausal women must be under treatment with luteinizing hormone-releasing hormone (LHRH) analogues.

Eligibility criteria: Inclusion Criteria:

1. Female patients over 18 years of age.
2. Pre-menopausal women provided they are being treated with a LHRH analogue for at least 28 days (if shorter, post-menopausal levels of serum estradiol/Follicle-stimulating hormone (FSH) must be confirmed analytically) prior to study entry or post- menopausal women as defined by any of the following criteria:

   1. Age ≥60 years;
   2. Age \<60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and serum estradiol and/or FSH level within the laboratory's reference range for postmenopausal females;
   3. Documented bilateral oophorectomy.
3. Eastern Cooperative Oncology Group (ECOG) performance status lower or equal to 1.
4. Life expectancy greater or equal to 12 weeks.
5. Histologically proven diagnosed of ABC not amenable to curative treatment.
6. Documented recurrent ER-positive and/or progesterone receptor (PgR)-positive (with ≥1% positive stained cells (according to NCCN National Comprehensive Cancer Network and ASCO American Society of Clinical Oncology guidelines) and HER2-negative (0-1+ by immunohistochemistry (IHC) or 2+ and negative by in situ hybridization (ISH) test) breast cancer in the advanced setting.
7. Radiological or clinical evidence of disease progression on first- line combination of palbociclib plus endocrine therapy (aromatase inhibitor (AI) or fulvestrant). Patients previously treated with the combination of palbociclib and tamoxifen will be excluded.
8. Patients have achieved clinical benefit criteria to a first-line palbociclib-based endocrine regimen (defined as at least stable disease ≥ 24 weeks or partial or complete response confirmed or unconfirmed).
9. Patients must have been treated with a stable minimum dose of 75 mg palbociclib during the last 2 cycles of the prior palbociclib-based regimen.
10. Last dose of palbociclib administered not later than 8 weeks and not earlier than 7 days from study entry, with the exception of patients relapsing on a palbociclib-based regimen in the adjuvant setting.
11. Patients should not have been treated in the advanced setting with at least one of these endocrine therapy options: either fulvestrant or AI.
12. Patients must have measurable disease or evaluable disease according to RECIST criteria v.1.1. Patients with only bone lesions are eligible.
13. Willingness and ability to provide tumor biopsy (if feasible) both at the time of the inclusion and after disease progression in order to perform exploratory studies. If not feasible, patient eligibility should be evaluated by a Sponsor's qualified designee.
14. Patients agree to collection of blood samples (liquid biopsy) at the time of inclusion, after 2 weeks of treatment, and upon progression or study termination.
15. Adequate organ function: (Hematological, hepatic and renal)
16. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
17. Patients have been informed about the nature of study, and have agreed to participate in the study, and signed the informed consent form prior to participation in any study-related activities.
18. Resolution of all acute toxic effects of prior anti-cancer therapy to grade 1

Exclusion Criteria:

1. HR or HER2 unknown disease.
2. HER2-positive disease based on local laboratory results (performed by IHC / ISH test).
3. Locally ABC candidate for curative treatment.
4. Formal contraindication to endocrine therapy defined as visceral crisis and rapidly or symptomatic progressive visceral disease.
5. Prior therapy with any other CDK4/6 inhibitor different from palbociclib.
6. Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth. Patients with a history of CNS metastases or cord compression are eligible if they have been definitively treated and are clinically stable off anticonvulsants and steroids for at least 4 weeks before randomization.
7. Patients are currently receiving food or drugs known to be strong inducers or inhibitors of CYP3A4.
8. Current or prior malignancy which could affect compliance with the protocol or interpretation of results. Patients with curatively- treated non-melanoma skin cancer, non-muscle-invasive bladder cancer, or carcinoma in situ, among others, are generally eligible.
9. No other systemic therapy for metastatic disease including chemotherapy, immunotherapy, targeted therapy (small molecules/ monoclonal antibodies), or endocrine therapy excluding first-line palbociclib-based regimen.
10. Major surgery (defined as requiring general anesthesia) or significant traumatic injury within 2 weeks of start of study drug, or patients who have not recovered from the side effects of any major surgery, or patients who may require major surgery during the study.
11. Radiotherapy or limited-field palliative radiotherapy within 7 days prior to study enrolment, or patients who have not recovered from radiotherapy-related toxicities to baseline or grade ≤ 1 and/or from whom ≥ 25% of the bone marrow has been previously irradiated.
12. Use of concurrent investigational agents or other concomitant anticancer therapies.
13. Active bleeding diathesis, previous history of bleeding diathesis, or chronic anti-coagulation treatment (the use of low molecular weight heparin is allowed as soon as it is used as prophylaxis intention).
14. Serious concomitant systemic disorder (e.g., active infection including HIV, or cardiac disease) incompatible with the study (at the discretion of investigator).
15. Unable to swallow capsules or tablets.
16. History of malabsorption syndrome or other condition that would interfere with enteral absorption.
17. Any of the following within 6 months of randomization:

    myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI-CTCAE v.5.0 grade ≥2, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism.
18. Uncontrolled electrolyte disorders of NCI-CTCAE v.5.0 grade ≥ 2.
19. Known hypersensitivity to palbociclib or any of its excipients.

Primary outcomes:
measure: PFS (Progression-free survival)
timeFrame: Baseline up to 29 months
Secondary outcomes:
measure: Safety AEs
timeFrame: Baseline up to 29 months
measure: Efficacy (ORR)
timeFrame: Baseline up to 29 months
measure: Efficacy (Quality of Life)
timeFrame: Baseline up to 42 months
measure: Efficacy of subgroup analysis
timeFrame: Baseline up to 42 months
measure: Compare efficacy
timeFrame: Baseline up to 42 months
measure: Exploratory objectives (molecular markers)
timeFrame: Baseline up to 42 months
measure: Exploratory objectives (intrinsic molecular subtypes)
timeFrame: Baseline up to 42 months
Other outcomes:
Locations:
city: Besançon
country: France
facility: Hôpital Jean Minjoz
city: Bordeaux
country: France
facility: Polyclinique Bordeaux Nord Aquitaine
city: Dijon
country: France
facility: Centre Georges François Leclerc
city: La Roche-sur-Yon
country: France
facility: CHD Vendee
city: Paris
country: France
facility: Hopital Europeen Georges Pompidou
city: Paris
country: France
facility: Hôpital Tenon AP-HP
city: Strasbourg
country: France
facility: Centre Paul Strauss
city: Dresden
country: Germany
facility: University Hospital Dresden-GYN
city: Essen
country: Germany
facility: Kliniken Essen Mitte
city: Essen
country: Germany
facility: Universitätsklinikum Essen Frauenklinik
city: Frankfurt
country: Germany
facility: AGAPLESION Markus Krankenhaus
city: Munich
country: Germany
facility: Technical University Munich
city: Münster
country: Germany
facility: UKM Brustzentrum
city: Potsdam
country: Germany
facility: Klinikum Ernst von Bergmann
city: Trier
country: Germany
facility: Klinikum Mutterhaus der Borromäerinnen Trier
city: Brescia
country: Italy
facility: Ospedale Civili Brescia
city: Milano
country: Italy
facility: Instituto Europeo di Oncologia
city: Prato
country: Italy
facility: Oncologia Medica Ospedale di Prato
city: Roma
country: Italy
facility: Policlinico Universitario Campus Bio-medico
city: Ljubljana
country: Slovenia
facility: Onkološki Inštitut Ljubljana
city: Maribor
country: Slovenia
facility: Univerzitetni klinicni center Maribor Oddelek za onkologijo
city: Badalona
country: Spain
facility: ICO Badalona
state: Barcelona
city: Castello
country: Spain
facility: Hospital Provincial de Castellón
state: Castelló
city: Terrassa
country: Spain
facility: Consorci Sanitari de Terrassa
state: Terrasa
city: A Coruña
country: Spain
facility: Centro Oncológico de Galicia
city: Barcelona
country: Spain
facility: Institut Català d'Oncologia Bellvitge
city: Barcelona
country: Spain
facility: H. Vall Hebrón
city: Barcelona
country: Spain
facility: Hospital del Mar
city: Bilbao
country: Spain
facility: Hospital de Basurto
city: Cáceres
country: Spain
facility: Hospital San Pedro de Alcantara
city: Girona
country: Spain
facility: Institut Català d'Oncologia
city: Lleida
country: Spain
facility: Hospital Arnau de Vilanova
city: Madrid
country: Spain
facility: Hospital Clinico San Carlos
city: Madrid
country: Spain
facility: Hospital Universitario Sanchinarro
city: Madrid
country: Spain
facility: Hospital La Paz
city: Málaga
country: Spain
facility: Hospital Regional Universitario de Malaga
city: Palma De Mallorca
country: Spain
facility: Hospital Universitari Son Espases
city: Reus
country: Spain
facility: Hospital Sant Joan
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen de la Macarena
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen del Rocío
city: Valencia
country: Spain
facility: Instituto Valenciano de Oncología IVO
city: Valencia
country: Spain
facility: Hospital General Universitari de Valencia
city: Valencia
country: Spain
facility: Hospital Arnau de Vilanova de Valencia
city: Valencia
country: Spain
facility: Hospital Universitari i Politecnic La Fe
city: Vigo
country: Spain
facility: Hospital Álvaro Cunqueiro
city: Zaragoza
country: Spain
facility: Hospital Lozano Blesa
city: Zaragoza
country: Spain
facility: Hospital Miguel Servet
city: Dartford
country: United Kingdom
facility: Darent Valley Hospital by Dartford and Gravesham NHS Trust
city: Glasgow
country: United Kingdom
facility: Beatson West of Scotland Cancer Center
city: London
country: United Kingdom
facility: Barts Cancer Institute
city: Maidstone
country: United Kingdom
facility: Kent Oncology Department
city: Swansea
country: United Kingdom
facility: Abertawe Bro Morgannwg University Local Health Board, Singleton Hospital
city: Truro
country: United Kingdom
facility: Royal Cornwall Hospital NHS Trust
Study officials:
affiliation: MedSIR
name: José Perez
role: PRINCIPAL_INVESTIGATOR
References: